Develops drugs for neurologic diseases, including Pompe disease and epilepsy.
Dec 2025Revenue $1.40M/yrExpenses $4.49M/yr
No trendCash runway ≈ 1.4 years from Jun 2026
Figures by year
When will Avenue Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $1.40M and expenses $4.49M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $1.40M | $4.49M | −$3.08M |
| Dec 2024 | $0.00 | $11.3M | −$11.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.